




ALKEM

ALKEM LABORATORIES LTD.

Regd. Office : "ALKEM HOUSE", Senapati Bapat Marg,
Lower Parel, MUMBAI 400 013. Phone : 3982 9999, Fax : 022 - 2495 2955
Email : contact@alkem.com Website : www.alkemlabs.com
CIN no.:- U00305MH1973PLC174201



Serial No. BM/2/2016-2017

1st August, 2016

**To,
The Board of Directors
Alkem Laboratories Limited**

NOTICE OF THE NEXT BOARD MEETING

Dear Sir / Madam

NOTICE is hereby given that the next meeting of the Board of Directors of the Company will be held on Friday, 12th August, 2016 at 11.00 a.m. at Grand Cru Salon, 8th Floor, The St. Regis Mumbai, 462 Senapati Bapat Marg, Lower Parel, Mumbai - 400013, to transact the following business:

1. To grant leave of absence to Directors, if any.
2. To confirm the minutes of the meeting of the Board of Directors held on 27th May, 2016.
3. To take note of minutes of the meetings of the following Committees of the Board of Directors:
 - (i) Corporate Social Responsibility Committee meeting held on 22nd April, 2016;
 - (ii) Nomination & Remuneration Committee meeting held on 26th May, 2016;
 - (iii) Audit Committee meeting held on 26th May, 2016 and
 - (iv) Stakeholders Relationship Committee meeting held on 26th May, 2016.
4. To take note of the minutes of the meetings of the Board of Directors of the unlisted subsidiaries of the Company.
5. To take note of the statement of all significant transactions and arrangements entered into by unlisted subsidiaries for the quarter ended 30th June, 2016.
6. To consider and review business performance of the Company for the quarter ended 30th June, 2016.



ALKEM

ALKEM LABORATORIES LTD.

Regd. Office : "ALKEM HOUSE", Senapati Bapat Marg,
Lower Parel, MUMBAI 400 013. Phone : 3982 9999, Fax : 022 - 2495 2955
Email : contact@alkem.com Website : www.alkemlabs.com
CIN no.:- U00305MH1973PLC174201



7. To consider and approve Standalone and Consolidated Unaudited Financial Results for the quarter ended 30th June, 2016 as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (hereinafter referred to as SEBI (LODR) Regulations).
8. To take on record Limited Review Report on Standalone and Consolidated Unaudited Financial Results for the quarter ended 30th June, 2016 as per Regulation 33(1)(d) of SEBI (LODR) Regulations.
9. To take on record certificate on financial results from Chief Executive Officer and Chief Financial Officer of the Company under Regulation 17(8) of SEBI (LODR) Regulations.
10. To consider and approve the Cost Audit Report for Bulk Drugs and Formulations for the financial year ended 31st March, 2016.
11. To consider and approve re-appointment of Mr. Suresh Shenoy as Cost Auditor of the Company for the financial year 2016-2017.
12. To consider and approve further investment upto Rs. 25 Crores in the equity share capital of Cachet Pharmaceuticals Private Limited, a subsidiary of the Company.
13. To consider and approve the increase in the credit facility availed from DBS Bank Limited.
14. To review the details of foreign exchange exposures and steps taken by management to limit the risks of adverse exchange rate movement as per Regulation 17(7) of SEBI (LODR) Regulations.
15. To take on record the documents filed with the Exchanges during the quarter ended 30th June, 2016.
16. To review the Compliance Reports pertaining to all applicable laws to the Company as per Regulation 17(3) of SEBI (LODR) Regulations for the quarter ended 30th June, 2016.
17. To take note of information required to be placed before the Board in terms of Regulation 17(7) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.



ALKEM

ALKEM LABORATORIES LTD.

Regd. Office : "ALKEM HOUSE", Senapati Bapat Marg,
Lower Parel, MUMBAI 400 013. Phone : 3982 9999, Fax : 022 - 2495 2955
Email : contact@alkem.com Website : www.alkemlabs.com
CIN no.:- U00305MH1973PLC174201



18. To consider and approve the opening of Current Account and EEFC Account with Shamrao Vithal Co-op. Bank, S V Marg Branch, Mumbai.
19. To consider and approve the closure of the Bank Accounts of the Company.
20. To consider and approve the change in authorised signatories of Bank Accounts of the Company.
21. To take note of Notice of disclosure of interest received from the Directors of the Company under section 184(1) of Companies Act, 2013.
22. To take note of the Register of contracts or arrangements, if any in which Directors are interested.
23. Any other matter with the permission of the Chair.

The Members of the Board are requested to please make it convenient to attend the meeting.

Yours faithfully

For Alkem Laboratories Limited

Samprada Singh
Chairman Emeritus
DIN: 00760279